PMBCL
Haematology · 2018–2020
2decisions
1medicine
2carried consumer input
4individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Treatment of relapsed or refractory primary mediastinal B-cell lymphoma (R/R PMBCL) in adult and paediatric patients who have refractory disease or have… | Mar 2020 | Recommended | 1 individuals Lymphoma Australia · Leukaemia Foundation |
| pembrolizumab Treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (R/R PMBCL) in adult and paediatric patients. | Nov 2018 | Not recommended | 3 individuals |
Who spoke
Lymphoma Australia · Leukaemia Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.